$ACER News
Last published 1mo ago
- 1mo agoGOOGLBBYACERASUS+6Google’s $899 Googlebook is a bet that you’ll buy a new laptop for GeminiTechCrunch
- 5mo agoAAPLGOOGLNVDAACERIrisGo, a startup backed by Andrew Ng, looks to become the AI desktop buddy you never knew you neededTechCrunch
- 1y agoACERApproval of Olpruva, Nda #214860 (Efficacy)FDA Approved DrugsApproval Date: 10/10/2025; Drug Name: Olpruva, Nda #214860; Active Ingredients: SODIUM PHENYLBUTYRATE; Company: Acer; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 214860
- 3y agoACERLeading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related ProposalsGlobeNewswireNEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 3y agoACER2353-TW992-HKHPE+2PC demand is back, says Acer CEO who sees robust growth in the 'foreseeable future'CNBCAcer CEO Jason Chen said that PC demand hit a bottom in May, but demand has come back since then.
- 3y agoACERLVOXPNTTWNKMoore Kuehn Encourages TWNK, LVOX, ACER, and PNT Investors to Contact Law FirmPR NewswireNEW YORK, Oct. 13, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoACERNXGNSUMAGEMoore Kuehn Encourages AGE, ACER, NXGN, and SUM Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoACERZVRAZevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial ProductGlobeNewswireProposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra's purchase of Acer's secured debt in capital efficient structure Zevra to assume commercialization efforts of
- 3y agoACERAcer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical EuropeGlobeNewswireNEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 3y agoACERAcer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireNEWTON, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 3y agoACERAcer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and FounderGlobeNewswirePromissory note extends cash runway into early Q3 2023 OLPRUVA™ expected to be available by prescription in the U.S. beginning July 5th NEWTON, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc.
- 3y agoACERAcer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate UpdateGlobeNewswireNEWTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 3y agoACERAcer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of ScheduleGlobeNewswireAvailability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at SIMD Annual Meeting indicated an interest in treating at least one of
- 3y agoACERAcer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswireNEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 3y agoACERAcer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment AttributesGlobeNewswireNEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 3y agoACERAcer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireNEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 3y agoACERAcer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a TrialGlobeNewswireNEWTON, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 3y agoACERAcer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program UpdateGlobeNewswireResults to be presented from a survey designed to quantify treatment preferences of healthcare providers for Urea Cycle Disorders (UCDs) OLPRUVA™ preliminary launch activities progressing; building out commercial
- 3y agoACERAcer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with MenopauseGlobeNewswireNEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 3y agoACERAZYOBIOLETON+1SWK Holdings Provides Portfolio Update Highlighting Recent AchievementsPR NewswireFourth Quarter and Full Year 2022 Financial Results to be Announced in March DALLAS, Jan. 31, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused
- 3y agoACERAcer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 MilestonesGlobeNewswireNEWTON, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of
- 3y agoACERAcer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the ProstateGlobeNewswireNEWTON, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and
- 3y agoACERAcer Therapeutics Compliant with All Nasdaq Listing CriteriaGlobeNewswireNEWTON, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and
- 3y agoACERRLFTFAcer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle DisordersGlobeNewswireNew FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that, if drawn, would extend cash runway into H2 2023 NEWTON, Mass. and GENEVA,
- 3y agoACERApproval of Olpruva, Nda #214860 (Type 5 - New Formulation or New Manufacturer)FDA Approved DrugsApproval Date: 12/22/2022; Drug Name: Olpruva, Nda #214860; Active Ingredients: SODIUM PHENYLBUTYRATE; Company: Acer Therapeutics Inc; Submission Status: Approval; Submission Classification: Type 5 - New Formulation or New Manufacturer; Application Number: 214860
- 3y agoACERAcer Therapeutics Announces $1.5M Private PlacementGlobeNewswireNEWTON, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 3y agoACERAcer Therapeutics Reports Q3 2022 Financial Results and Provides Corporate UpdateGlobeNewswireNEWTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
- 4y agoACERAcer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)GlobeNewswireNEWTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare
- 4y agoACERAZYOBIOLBTCY+2SWK Holdings Provides Portfolio Update Highlighting Recent AchievementsPR NewswireThird Quarter 2022 Financial Results to be Announced in Early November DALLAS, Oct. 18, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science focused
- 4y agoACERAcer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stress DisorderGlobeNewswireLicensed exclusive worldwide rights from Emory University to patents and patent applications for certain methods of treating or preventing post-traumatic stress disorder (PTSD) with osanetant Osanetant targets a distinct group of brain cells in a regi
- 4y agoACERRLFTFAcer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium BenzoateGlobeNewswireNEWTON, Mass. and GENEVA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) (Acer) and RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief) today announced that the US Patent and Trademark Office (USPTO) has iss
- 4y agoACERAcer Therapeutics to Participate in August and September 2022 Investor ConferencesGlobeNewswireNEWTON, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant
- 4y agoACERAcer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate UpdateGlobeNewswireNEWTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant
- 4y agoACERRLFTFRelief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine DiseaseGlobeNewswireGENEVA, Switzerland and NEWTON, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief), and its collaboration partner, Acer Therapeutics Inc. (NASDAQ:ACER) (Acer), today announced that the Euro
- 4y agoACERRLFTFAcer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine DiseaseGlobeNewswireNEWTON, Mass. and GENEVA, Switzerland, July 28, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief), today announced the submission
- 4y agoACERRLFTFAcer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsGlobeNewswireNEWTON, Mass. and GENEVA, July 28, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief), today announced the U.S. Food and Drug Admi
- 4y agoACERAcer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDsGlobeNewswireNEWTON, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant u
- 4y agoACERRLFTFAcer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage FormGlobeNewswireNEWTON, Mass. and GENEVA, July 08, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief), today announced that the China National Int
- 4y agoACERAcer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos SyndromeGlobeNewswireNEWTON, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases wit
- 4y agoACERAcer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating OfficerGlobeNewswireNEWTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant u
- 4y agoACERRLFTFAcer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001GlobeNewswireCiting the need to inspect a third-party contract packaging manufacturer, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) The FDA has not raised any approvability concerns related to the efficacy, safety or ph
- 4y agoACERAcer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001GlobeNewswireNEWTON, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant u
- 4y agoACERAcer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate UpdateGlobeNewswireNEWTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant u
- 4y agoACERAcer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome PatientsGlobeNewswireNEWTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant un
- 4y agoACERRLFTFAcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International ConferenceGlobeNewswireNEWTON, Mass. and GENEVA, May 06, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) ("Relief"), today announced the presentation of data
- 4y agoACERRLFTFRLFTYAcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International ConferenceACCESS NewswireNEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA ((SIX:RLF, OTCQB:RLFTF, RLFTY)) ("Relief"), today announced the presentation of da
- 4y agoACERAcer Therapeutics to Participate in H.C. Wainwright Global Investment ConferenceGlobeNewswireNEWTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant un
- 4y agoACERRLFTFAcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual MeetingGlobeNewswireNEWTON, Mass. and GENEVA, April 12, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) ("Relief"), today announced the presentation of da
- 4y agoACERRLFTFRLFTYAcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual MeetingACCESS NewswireNEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / April 12, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), today announced the presentatio
- 4y agoACERAcer Therapeutics' EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos SyndromeGlobeNewswireNEWTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant